News AZ's Tagrisso gets NHS funding in Scotland SMC backs drug based on feedback from patients and doctors, after rejection by NICE.
News Pfizer breast cancer drug Ibrance rejected by NICE Ibrance too expensive at almost £80,000 per course.
News Janssen's Imbruvica recommended in CLL J&J unit awaiting decisions in two more blood cancer uses.
News Pharma criticises 'heavy handed' NICE affordability test NHS England and NICE are attempting to reduce budget impact of drugs.
News Myeloma drugs Darzalex and Kyprolis rejected in Scotland SMC says "no" to Amgen and Janssen multiple myeloma drugs.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.